These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 23370522

  • 1. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
    Tsuji D.
    Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
    [Abstract] [Full Text] [Related]

  • 2. Metabolic correction in microglia derived from Sandhoff disease model mice.
    Tsuji D, Kuroki A, Ishibashi Y, Itakura T, Itoh K.
    J Neurochem; 2005 Sep; 94(6):1631-8. PubMed ID: 16092933
    [Abstract] [Full Text] [Related]

  • 3. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.
    Toro C, Zainab M, Tifft CJ.
    Neurosci Lett; 2021 Nov 01; 764():136195. PubMed ID: 34450229
    [No Abstract] [Full Text] [Related]

  • 4. Novel bicistronic lentiviral vectors correct β-Hexosaminidase deficiency in neural and hematopoietic stem cells and progeny: implications for in vivo and ex vivo gene therapy of GM2 gangliosidosis.
    Ornaghi F, Sala D, Tedeschi F, Maffia MC, Bazzucchi M, Morena F, Valsecchi M, Aureli M, Martino S, Gritti A.
    Neurobiol Dis; 2020 Feb 01; 134():104667. PubMed ID: 31682993
    [Abstract] [Full Text] [Related]

  • 5. Improvement of motor and behavioral activity in Sandhoff mice transplanted with human CD34+ cells transduced with a HexA/HexB expressing lentiviral vector.
    Beegle J, Hendrix K, Maciel H, Nolta JA, Anderson JS.
    J Gene Med; 2020 Sep 01; 22(9):e3205. PubMed ID: 32335981
    [Abstract] [Full Text] [Related]

  • 6. Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates.
    Tsuji D, Kuroki A, Ishibashi Y, Itakura T, Kuwahara J, Yamanaka S, Itoh K.
    J Neurochem; 2005 Mar 01; 92(6):1497-507. PubMed ID: 15748167
    [Abstract] [Full Text] [Related]

  • 7. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ, Trasler JM, Igdoura S, Michaud J, Hanal N, Gravel RA.
    Hum Mol Genet; 1997 Oct 01; 6(11):1879-85. PubMed ID: 9302266
    [Abstract] [Full Text] [Related]

  • 8. Western blotting analysis of the beta-hexosaminidase alpha- and beta-subunits in cultured fibroblasts from cases of various forms of GM2 gangliosidosis.
    Utsumi K, Tsuji A, Kase R, Tanaka A, Tanaka T, Uyama E, Ozawa T, Sakuraba H, Komaba Y, Kawabe M, Iino Y, Katayama Y.
    Acta Neurol Scand; 2002 Jun 01; 105(6):427-30. PubMed ID: 12027830
    [Abstract] [Full Text] [Related]

  • 9. Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.
    Tsuji D, Akeboshi H, Matsuoka K, Yasuoka H, Miyasaki E, Kasahara Y, Kawashima I, Chiba Y, Jigami Y, Taki T, Sakuraba H, Itoh K.
    Ann Neurol; 2011 Apr 01; 69(4):691-701. PubMed ID: 21520232
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic evaluation of GM2 gangliosidoses by ELISA using anti-GM2 ganglioside antibodies.
    Tsuji D, Higashine Y, Matsuoka K, Sakuraba H, Itoh K.
    Clin Chim Acta; 2007 Mar 01; 378(1-2):38-41. PubMed ID: 17196574
    [Abstract] [Full Text] [Related]

  • 11. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L, Przybilla MJ, Tăbăran AF, Overn P, O'Sullivan MG, Jiang X, Sidhu R, Kell PJ, Ory DS, Whitley CB.
    Gene Ther; 2020 May 01; 27(5):226-236. PubMed ID: 31896760
    [Abstract] [Full Text] [Related]

  • 12. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
    Gort L, de Olano N, Macías-Vidal J, Coll MA, Spanish GM2 Working Group.
    Gene; 2012 Sep 10; 506(1):25-30. PubMed ID: 22789865
    [Abstract] [Full Text] [Related]

  • 13. Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
    Itakura T, Kuroki A, Ishibashi Y, Tsuji D, Kawashita E, Higashine Y, Sakuraba H, Yamanaka S, Itoh K.
    Biol Pharm Bull; 2006 Aug 10; 29(8):1564-9. PubMed ID: 16880605
    [Abstract] [Full Text] [Related]

  • 14. Brain endothelial specific gene therapy improves experimental Sandhoff disease.
    Dogbevia G, Grasshoff H, Othman A, Penno A, Schwaninger M.
    J Cereb Blood Flow Metab; 2020 Jun 10; 40(6):1338-1350. PubMed ID: 31357902
    [Abstract] [Full Text] [Related]

  • 15. Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
    Akeboshi H, Chiba Y, Kasahara Y, Takashiba M, Takaoka Y, Ohsawa M, Tajima Y, Kawashima I, Tsuji D, Itoh K, Sakuraba H, Jigami Y.
    Appl Environ Microbiol; 2007 Aug 10; 73(15):4805-12. PubMed ID: 17557860
    [Abstract] [Full Text] [Related]

  • 16. Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.
    Lahey HG, Webber CJ, Golebiowski D, Izzo CM, Horn E, Taghian T, Rodriguez P, Batista AR, Ellis LE, Hwang M, Martin DR, Gray-Edwards H, Sena-Esteves M.
    Mol Ther; 2020 Oct 07; 28(10):2150-2160. PubMed ID: 32592687
    [Abstract] [Full Text] [Related]

  • 17. Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model.
    Kitakaze K, Mizutani Y, Sugiyama E, Tasaki C, Tsuji D, Maita N, Hirokawa T, Asanuma D, Kamiya M, Sato K, Setou M, Urano Y, Togawa T, Otaka A, Sakuraba H, Itoh K.
    J Clin Invest; 2016 May 02; 126(5):1691-703. PubMed ID: 27018595
    [Abstract] [Full Text] [Related]

  • 18. Genetics and Therapies for GM2 Gangliosidosis.
    Cachon-Gonzalez MB, Zaccariotto E, Cox TM.
    Curr Gene Ther; 2018 May 02; 18(2):68-89. PubMed ID: 29618308
    [Abstract] [Full Text] [Related]

  • 19. Introduction of an N-glycan sequon into HEXA enhances human beta-hexosaminidase cellular uptake in a model of Sandhoff disease.
    Matsuoka K, Tsuji D, Aikawa S, Matsuzawa F, Sakuraba H, Itoh K.
    Mol Ther; 2010 Aug 02; 18(8):1519-26. PubMed ID: 20571546
    [Abstract] [Full Text] [Related]

  • 20. Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts.
    Kitakaze K, Tasaki C, Tajima Y, Hirokawa T, Tsuji D, Sakuraba H, Itoh K.
    Biochem Biophys Rep; 2016 Sep 02; 7():157-163. PubMed ID: 28955902
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.